{"id":"influenza-vaccine-gsk1562902a-formulation-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSK1562902A Formulation 2 is an inactivated influenza vaccine designed to induce both humoral and cellular immune responses against circulating influenza strains. By presenting viral antigens to the immune system, the vaccine trains B and T cells to recognize and neutralize the virus upon natural exposure, reducing infection risk and disease severity.","oneSentence":"This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:28.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT00430521","phase":"PHASE2","title":"Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-05","conditions":"Influenza, Influenza Vaccines","enrollment":512},{"nctId":"NCT00502593","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Influenza","enrollment":138},{"nctId":"NCT01379937","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-28","conditions":"Influenza","enrollment":520},{"nctId":"NCT00319098","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Influenza","enrollment":5075},{"nctId":"NCT00506350","phase":"PHASE2","title":"Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-01","conditions":"Influenza","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Influenza vaccine GSK1562902A Formulation 2","genericName":"Influenza vaccine GSK1562902A Formulation 2","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection. Used for Seasonal influenza prevention in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}